HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples

BackgroundInfection with HIV-1 is characterized by genetic diversity such that specific viral subtypes are predominant in specific geographical areas. The genetic variation in HIV-1 pol and env genes is responsible for rapid development of resistance to current drugs. This variation has influenced disease progression among the infected and necessitated the search for alternative drugs with novel targets. Though successfully used in developed countries, these novel drugs are still limited in resource-poor countries. The aim of this study was to determine HIV-1 subtypes, recombination, dual infections and viral tropism of HIV-1 among Kenyan patients prior to widespread use of antiretroviral drugs.MethodsRemnant blood samples from consenting sexually transmitted infection (STI) patients in Nairobi were collected between February and May 2001 and stored. Polymerase chain reaction and cloning of portions of HIV-1 gag, pol and env genes was carried out followed by automated DNA sequencing.ResultsTwenty HIV-1 positive samples (from 11 females and 9 males) were analyzed. The average age of males (32.5 years) and females (26.5 years) was significantly different (p value < 0.0001). Phylogenetic analysis revealed that 90% (18/20) were concordant HIV-1 subtypes: 12 were subtype A1; 2, A2; 3, D and 1, C. Two samples (10%) were discordant showing different subtypes in the three regions. Of 19 samples checked for co-receptor usage, 14 (73.7%) were chemokine co-receptor 5 (CCR5) variants while three (15.8%) were CXCR4 variants. Two had dual/mixed co-receptor use with X4 variants being minor population.ConclusionHIV-1 subtype A accounted for majority of the infections. Though perceived to be a high risk population, the prevalence of recombination in this sample was low with no dual infections detected. Genotypic co-receptor analysis showed that most patients harbored viruses that are predicted to use CCR5.

[1]  I. Thior,et al.  Human immunodeficiency virus type 1 subtypes differ in disease progression. , 1999, The Journal of infectious diseases.

[2]  P. Piot,et al.  Genetic variability of HIV type 1 in Kenya. , 1994, AIDS research and human retroviruses.

[3]  P. Kaleebu,et al.  Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. , 2002, The Journal of infectious diseases.

[4]  L. Ruiz,et al.  Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. , 2007, The Journal of antimicrobial chemotherapy.

[5]  F. Brun-Vézinet,et al.  Identification of a new human immunodeficiency virus type 1 distinct from group M and group O , 1998, Nature Medicine.

[6]  M. Wainberg.  Perspectives on antiviral drug development. , 2009, Antiviral research.

[7]  Peter Piot,et al.  Joint United Nations Program on HIV/AIDS (UNAIDS) , 1997 .

[8]  O. Hamouda.  [Epidemiology of HIV and AIDS]. , 2010, MMW Fortschritte der Medizin.

[9]  Bernard Hirschel,et al.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.

[10]  M. Thomson,et al.  Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. , 2002, The Lancet. Infectious diseases.

[11]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[12]  B. Renjifo.  Molecular Diagnosis of HIV Infection , 2002 .

[13]  T. Shioda,et al.  Anti‐retroviral drug resistance‐associated mutations among non‐subtype B HIV‐1‐infected Kenyan children with treatment failure , 2007, Journal of medical virology.

[14]  S. Coppens,et al.  Simplified Strategy for Detection of Recombinant Human Immunodeficiency Virus Type 1 Group M Isolates bygag/env Heteroduplex Mobility Assay , 2000, Journal of Virology.

[15]  S. Coppens,et al.  Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities. , 2000, Journal of virology.

[16]  David W. Williamson,et al.  Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.

[17]  B. Clotet,et al.  A Double-Blind , Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R 5 HIV-1 , 2009 .

[18]  P. Sharp,et al.  Genetic diversity of HIV-1: the moving target. , 2000, AIDS.

[19]  T. Schulz,et al.  A chimpanzee rhadinovirus sequence related to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8: increased detection after HIV-1 infection in the absence of disease , 2000, AIDS.

[20]  Sebastian Bonhoeffer,et al.  The HIV coreceptor switch: a population dynamical perspective. , 2005, Trends in microbiology.

[21]  M. Essex,et al.  HIV-1 Subtypes and Recombinants , 2002 .

[22]  Dan Turner,et al.  Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. , 2003, The Journal of antimicrobial chemotherapy.

[23]  Eoin Coakley,et al.  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  U. Alam,et al.  Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants , 2002, AIDS.

[25]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[26]  B. Korber,et al.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.

[27]  D. Ho,et al.  Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. , 2001, AIDS research and human retroviruses.

[28]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[29]  P. Harrigan,et al.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.

[30]  Roderic D. M. Page,et al.  TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..

[31]  B. Clotet,et al.  A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. , 2009, The Journal of infectious diseases.

[32]  J. Overbaugh,et al.  Phylogenetic evaluation of Kenyan HIV type 1 isolates. , 1997, AIDS research and human retroviruses.

[33]  J. Carr,et al.  Circulating recombinant form CRF02_AG in South America. , 2003, AIDS research and human retroviruses.

[34]  J. Nie,et al.  Impact of HIV‐1 genetic diversity in China on the measurement of viral load , 2008, Journal of medical virology.